Loading…
Loading…
RICHLAND, WA / ACCESSWIRE / March 28, 2024 / GlobeStar Therapeutics Corporation (OTC PINK:GSTC) (GSTC), is a clinical stage pharmaceutical company focused on advancing new therapies for Multiple Sclerosis (MS) and other neurological diseases, including but not limited to Rheumatoid Arthritis (RA), released on March 11, 2024 its fiscal year first quarter financials for the quarter ended 12/31/2023. The Company reported that $42,800 of cash was used in operating activities vs.
RICHLAND, WA / ACCESSWIRE / November 2, 2023 / GlobeStar Therapeutics Corporation (OTC PINK:GSTC), (GSTC), a clinical-stage pharmaceutical company focused on advancing new therapies for Multiple Sclerosis (MS) and other neurological diseases today announced that building on its recent agreement with SMI HealthCare LLC (SMIHC) to manage an initial clinical trial, regulatory filings, intellectual property rights filings, manufacturing, sales and distribution in India, Southeast Asia, Africa, and the Middle East. Globestar has also entered into a definitive agreement with Advanced Innovative Partners (AIP) for AIP to provide advice to GlobeStar and SMIHC on the global design, strategy and execution of clinical trials, regulatory filings, intellectual property rights filings, and manufacturing for Project Amethyst™.
RICHLAND, WA / ACCESSWIRE / September 28, 2023 / GlobeStar Therapeutics Corporation (OTC PINK:GSTC) (GSTC), a clinical-stage pharmaceutical company focused on advancing new therapies for Multiple Sclerosis (MS) and other neurological diseases today announced that it has entered into a definitive agreement with SMI HealthCare LLC (SMIHC) to manage an initial clinical trial, regulatory filings, intellectual property rights filings, manufacturing, sales and distribution in India, Southeast Asia, Africa, and the Middle East, excluding Israel and Iraq, and for government and private aid organizations, for GlobeStar's patented Multiple Sclerosis treatment. GSTC is the exclusive worldwide licensee for Project Amethyst™, including all patents and patent applications relating thereto, including U.S. Patent #10610592.
Company will move from the Pink tier to QB tier effective immediately while retaining the same ticker symbol. RICHLAND, WA / ACCESSWIRE / October 11, 2021 / GlobeStar Therapeutics Corporation (OTCQB:GSTC) ( www.globestarthera.com ) headquartered in Richland, Washington, is a fast-growing company focused on providing medical research, development, and treatments for disease.
Company has made progress with a major medical center in the Northeast and identified a path forward for this pharmaceutical. RICHLAND, WA / ACCESSWIRE / October 4, 2021 / GlobeStar Therapeutics Corporation (OTC PINK:GSTC) ( www.globestarthera.com ), headquartered in Richland, Washington, is a fast-growing company focused on providing medical research, development, and treatments for disease.
Company has made significant progress and identified a path forward for this pharmaceutical. RICHLAND, WA / ACCESSWIRE / September 20, 2021 / GlobeStar Therapeutics Corporation (OTCBB: GSTC) has filed its latest 8K statement and Edgar filing today.
New website goes live in tandem with a major branding campaign to be found in USA Today. RICHLAND, WA / ACCESSWIRE / July 21, 2021 / GlobeStar Therapeutics Corporation (OTC PINK:GSTC) is launching its new website at www.globestarthera.com over the next 24 hours.
RICHLAND, WA / ACCESSWIRE / July 15, 2021 / GlobeStar Therapeutics Corporation has partnered with the Washington Football Team Yearbook producers for inclusion in their annual book. GlobeStar Therapeutics Corporation (OTC PINK:GSTC) is partnering with the producers of the Washington Football Team Yearbook for inclusion in their 2021-2022 guide.
No recent filings indexed.